Jon Congleton
Director Ejecutivo en MINERALYS THERAPEUTICS, INC. .
Fortuna: 16 M $ al 30/04/2024
Perfil
Jon Congleton is currently the Chief Executive Officer & Director at Mineralys Therapeutics, Inc. and an Operating Partner at Catalys Pacific LLC.
Previously, he served as the President & Chief Executive Officer at Alpine Immune Sciences, Inc. and the President, Chief Executive Officer & Director at Ipi Legacy Liquidation Co. He also held the position of President, Chief Executive Officer & Director at Nivalis Therapeutics, Inc. from 2014 to 2017.
Prior to that, he worked as the Senior VP-Global Brand Strategic Marketing at Teva Pharmaceutical Industries Ltd.
and as the Vice President & General Manager at Teva Neuroscience, Inc. Mr. Congleton completed his undergraduate degree at Kansas State University.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 15/03/2024 | 1 454 235 ( 2.93% ) | 16 M $ | 30/04/2024 |
Cargos activos de Jon Congleton
| Empresas | Cargo | Inicio |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Director Ejecutivo | 01/11/2020 |
Catalys Pacific LLC
 Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Inversor de Capital Privado | - |
Antiguos cargos conocidos de Jon Congleton.
| Empresas | Cargo | Fin |
|---|---|---|
| IPI LEGACY LIQUIDATION CO | Director Ejecutivo | 05/05/2020 |
Nivalis Therapeutics, Inc.
 Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Director Ejecutivo | 15/01/2017 |
| ALPINE IMMUNE SCIENCES, INC. | Director Ejecutivo | 01/01/2017 |
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Ventas & Marketing | - |
Teva Neuroscience, Inc.
 Teva Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Teva Neuroscience, Inc. developed and marketed drugs for neurological disorders. The company's product COPAXONE was used to reduce relapses caused by relapsing-remitting multiple sclerosis. It also offered treatment for Parkinson's disease. Teva Neuroscience was founded in 1997 and was located in Kansas City, MO | Corporate Officer/Principal | - |
Formación de Jon Congleton.
| Kansas State University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 4 |
|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LIMITED | Health Technology |
| IPI LEGACY LIQUIDATION CO | Health Technology |
| ALPINE IMMUNE SCIENCES, INC. | Health Technology |
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| Empresas privadas | 3 |
|---|---|
Teva Neuroscience, Inc.
Teva Neuroscience, Inc. Pharmaceuticals: MajorHealth Technology Teva Neuroscience, Inc. developed and marketed drugs for neurological disorders. The company's product COPAXONE was used to reduce relapses caused by relapsing-remitting multiple sclerosis. It also offered treatment for Parkinson's disease. Teva Neuroscience was founded in 1997 and was located in Kansas City, MO | Health Technology |
Nivalis Therapeutics, Inc.
Nivalis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nivalis Therapeutics, Inc. is a clinical stage pharmaceutical company, which engages in discovery, development, and commercialization of product for patients with cystic fibrosis. Its product includes N91115, a small molecule that addresses a defect in the cystic fibrosis transmembrane conductance regulator. The company was founded in 2008 and is headquartered in Boulder, CO. | Health Technology |
Catalys Pacific LLC
Catalys Pacific LLC Investment ManagersFinance Catalys Pacific LLC (Catalys Pacific) is a venture capital firm founded in 2018 by BT Slingsby. The firm is headquartered in Cayman Islands. | Finance |
- Bolsa de valores
- Insiders
- Jon Congleton
